No title
Per- and polyfluoroalkyl substances (PFAS) are becoming an important regulatory and tech-nical concern for the pharmaceutical industry due to their high environmental persistence, po-tential health risks, broad use across many industrial production fields and growing pressure for their regulation in consumer products. The pharmaceutical industry is particularly at risk for PFAS, due to their stric
